Alvotech Signs an Exclusive License Agreement with DKSH for AVT02 (biosimilar, adalimumab) in Asia

 Alvotech Signs an Exclusive License Agreement with DKSH for AVT02 (biosimilar, adalimumab) in Asia

Alvotech Signs an Exclusive License Agreement with DKSH for AVT02 (biosimilar, adalimumab) in Asia

Shots:

  • Alvotech will be responsible for the development and supply of AVT02 in selected APAC market, while DKSH will be responsible for the registration and commercialization of the therapy
  • The alliance allows the Alvotech to gain access to DKHS’s commercial expertise, which will aid patients to get benefited with high-quality biosimilar therapies
  • AVT02 is a biosimilar referencing AbbVie’s Humira, which is indicated to treat RA, AS, PP, PsO, UC & CD with its anticipated regulatory filing to the EMA & the US FDA in H2’20

Click here ­to­ read full press release/ article | Ref: Alvotech | Image: Contract Pharma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post